GARDP and Japan’s National Center for Global Health andMedicine signed an MOU to boost clinical research activities
22 July 2022, Geneva/Tokyo – On 16 June, the Global Antibiotic Research and DevelopmentPartnership (GARDP) and the National Center for Global Health and Medicine (NCGM) signed aMemorandum of Understanding (MOU) to work on building a clinical research network in Asia andworldwide.

As part of the MOU, GARDP and NCGM plan to collaborate in generating clinical data to support
regulatory submission and public health evidence for treatments against drug-resistant infections inJapan, the Asian region and globally. GARDP and NCGM also plan to support regulatory submission
and access provisions for treatments developed by GARDP.
The MOU also highlights the plan to conduct clinical and epidemiological surveillance to gather
evidence on levels of drug-resistant infections in key populations, as well as conducting specificclinical investigations to support the appropriate use of antibiotics in patients.
“This collaboration with Japan’s NCGM will help us boost clinical research activities in Asia andacross regions, which are urgently needed to develop new and improved treatments for drug-resistantinfections,” said Manica Balasegaram, GARDP’s Executive Director.
NCGM is one of the world's leading research institutes that operates research centers for international
clinical studies related to controlling emerging and re-emerging infectious diseases, including COVID19, HIV/AIDS, tuberculosis, malaria, and Neglected Tropical Diseases (NTDs).
“We look forward to working on studies with GARDP to tackle infectious diseases such as neonatal
sepsis, which is a leading cause of death among newborns, particularly in countries with weak healthsystems,” said Norihiro Kokudo, NCGM’s President.

Japan, which will hold the presidency of the G7 in 2023, is committed to helping GARDP achieve its
goals, and it has made a one billion yen pledge to the organization from 2020 to 2025.

1

Global Antibiotic Research and Development Partnership (GARDP)
GARDP is a Swiss not-for-profit organization developing new treatments for drug-resistant infections
that pose the greatest threat to health. GARDP was created in 2016 by the World Health Organization(WHO) and the Drugs for Neglected Diseases initiative (DNDi) and legally founded in 2018 to ensurethat everyone who needs antibiotics receives effective and affordable treatment, no matter where theylive. It is developing new treatments to fight drug-resistant infections, with a focus on transmitted
infections, sepsis in newborns and infections in hospitalized adults and children. GARDP is working
with over 60 partners in more than 20 countries. Its work is funded by the governments of Australia,
Germany, Japan, Luxembourg, Monaco, Netherlands, South Africa, Switzerland, United Kingdom,
and the Canton of Geneva, as well as Médecins Sans Frontières and private foundations. GARDP isregistered under the legal name GARDP Foundation. www.gardp.org

National Center for Global Health and Medicine (NCGM)
NCGM is one of the six National Centers for Advanced and Specialized Medical Care (NationalCenters). NCGM has its roots in the military hospital established in 1868. In 2015, NCGM became
the National Research and Development Agency, one type of Independent Administrative Institution,and celebrated its 150th anniversary in 2018. NCGM consists of the Center Hospital, the Kohnodai
Hospital, the Research Institute, the Center for Clinical Sciences, the Bureau of International Health
Cooperation, the National College of Nursing, Japan and other organizations. NCGM undertakes
research and advanced comprehensive medical services on infectious and immune diseases andmetabolic diseases such as diabetes. NCGM also promotes international cooperation in healthcare andpursues the development of healthcare professionals. https://www.ncgm.go.jp/en/index.html